Oral vs transdermal estrogen therapy and vascular events: A systematic review and meta-analysis

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 11, 2015, Pages 4012-4020

  Mohammed, Khaled ^a   Dabrh, Abd Moain Abu ^a   Benkhadra, Khalid ^a   Al Nofal, Alaa ^a   Carranza Leon, Barbara G ^a   Prokop, Larry J ^a   Montori, Victor M ^a   Faubion, Stephanie S ^a   Murad, Mohammad Hassan ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVERSE EFFECTS; COMPARATIVE STUDY; ESTROGEN THERAPY; EVIDENCE BASED MEDICINE; FEMALE; HUMAN; MENOPAUSE; META ANALYSIS; OBSERVATIONAL STUDY; ORAL DRUG ADMINISTRATION; PROCEDURES; RISK FACTOR; STROKE; TRANSDERMAL PATCH; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; ESTROGEN REPLACEMENT THERAPY; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MENOPAUSE; OBSERVATIONAL STUDIES AS TOPIC; RISK FACTORS; STROKE; TRANSDERMAL PATCH; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84958658920     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-2237     Document Type: Review

References (31)

1. Utian WH. Psychosocial and socioeconomic burden of vasomotor symptoms in menopause: a comprehensive review. Health Qual Life Outcomes. 2005;3:47.
2. Grodstein F, Stampfer MJ, Manson JE, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. N Engl J Med. 1996;335:453-461.
3. Chae CU, Ridker PM, Manson JE. Postmenopausal hormone replacement therapy and cardiovascular disease. Thromb Haemost. 1997;78:770-780.
4. Simon JA. What if the Women's Health Initiative had used transdermal estradiol and oral progesterone instead? Menopause. 2014; 21:769-783.
5. L'hermite M, Simoncini T, Fuller S, Genazzani AR. Could transdermal estradiol progesterone be a safer postmenopausal HRT? A review. Maturitas. 2008;60:185-201.
6. Lowe GD, Upton MN, Rumley A, McConnachie A, O'Reilly DS, Watt GC. Different effects of oral and transdermal hormone replacement therapies on factor IX, APC resistance, t-PA, PAI and C-reactive protein-a cross-sectional population survey. Thromb Haemost. 2001;86:550-556.
7. Grodstein F, Manson JE, Stampfer MJ. Hormone therapy and coronary heart disease: the role of time since menopause and age at hormone initiation. J Womens Health (Larchmt). 2006;15:35-44.
8. Manson JE, Chlebowski RT, Stefanick ML, et al. Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials. JAMA. 2013;310:1353-1368.
9. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6:e1000097.
10. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Ottawa Hospital Research Institute. http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp.
11. Swiglo BA, Murad MH, Schünemann HJ, et al. A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. J Clin Endocrinol Metab. 2008;93:666-673.
12. Olié V, Plu-Bureau G, Conard J, HorellouMH,Canonico M, Scarabin PY. Hormone therapy and recurrence of venous thromboembolism among postmenopausal women. Menopause. 2011;18:488-493.
13. Roach RE, Lijfering WM, Helmerhorst FM, Cannegieter SC, Rosendaal FR, van Hylckama Vlieg A. The risk of venous thrombosis in women over 50 years old using oral contraception or postmenopausal hormone therapy. J Thromb Haemost. 2013;11:124-131.
14. Laliberté F, Dea K, Duh MS, Kahler KH, Rolli M, Lefebvre P. Does the route of administration for estrogen hormone therapy impact the risk of venous thromboembolism? Estradiol transdermal system versus oral estrogen-only hormone therapy. Menopause. 2011;18: 1052-1059.
15. Renoux C, Dell'Aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study. J Thromb Haemost. 2010;8:979-986.
16. Canonico M, Oger E, Plu-Bureau G, et al. Hormone therapy and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration and progestogens: the ESTHER study. Circulation. 2007;115:840-845.
17. Sweetland S, Beral V, Balkwill A, et al. Venous thromboembolism risk in relation to use of different types of postmenopausal hormone therapy in a large prospective study. J Thromb Haemost. 2012;10: 2277-2286.
18. Daly E, Vessey MP, Hawkins MM, Carson JL, Gough P, Marsh S. Risk of venous thromboembolism in users of hormone replacement therapy. Lancet. 1996;348:977-980.
19. Douketis JD, Julian JA, Kearon C, et al. Does the type of hormone replacement therapy influence the risk of deep vein thrombosis? A prospective case-control study. J Thromb Haemost. 2005;3:943-948.
20. Canonico M, Fournier A, Carcaillon L, et al. Postmenopausal hormone therapy and risk of idiopathic venous thromboembolism: results from the E3N cohort study. Arterioscler Thromb Vasc Biol. 2010;30:340-345.
21. Renoux C, Dell'aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested casecontrol study. BMJ. 2010;340:c2519.
22. de Vries CS, Bromley SE, Farmer RD. Myocardial infarction risk and hormone replacement: differences between products. Maturitas. 2006;53:343-350.
23. Hippisley-Cox J, Pringle M, Crown N, Coupland C. A case-control study on the effect of hormone replacement therapy on ischaemic heart disease. Br J Gen Pract. 2003;53:191-196.
24. Chilvers CE, Knibb RC, Armstrong SJ, Woods KL, Logan RF. Post menopausal hormone replacement therapy and risk of acute myocardial infarction-a case control study of women in the East Midlands, UK. Eur Heart J. 2003;24:2197-2205.
25. Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard O. Hormone therapy and risk of myocardial infarction: a national register study. Eur Heart J. 2008;29(21):2660-2668.
26. Scarabin PY,OgerE, Plu-Bureau G. Differential association of oral and transdermal oestrogen-replacement therapy with venous thromboembolism risk. Lancet. 2003;362:428-432.
27. Olié V, Canonico M, Scarabin PY. Risk of venous thrombosis with oral versus transdermal estrogen therapy among postmenopausal women. Curr Opin Hematol. 2010;17:457-463.
28. SareGM,Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J. 2008;29:2031-2041.
29. American College of Obstetricians and Gynecologists. ACOG committee opinion no. 556: postmenopausal estrogen therapy: route of administration and risk of venous thromboembolism. Obstet Gynecol. 2013;121:887-890.
30. Scarabin PY. Hormone therapy and venous thromboembolism among postmenopausal women. Front Horm Res. 2014;43:21-32.
31. Lobo RA. Where are we 10 years after the Women's Health Initiative? J Clin Endocrinol Metab. 2013;98:1771-1780.